Head of Drug Discovery, THerapeutic INnovations for Kids (THINK)Children’s Cancer Institute

Associate Professor Greg Arndt established the ACRF Drug Discovery Centre and is currently Head of Drug Discovery Biology for the THerapeutic INnovations for Kids (THINK) initiative at Children’s Cancer Institute (CCI) and Lead for the Luminesce Alliance Advanced Therapeutics Pipeline. His recent roles include Group Leader in Cancer Therapeutics Cooperative Research Centre, and Group Leader in the Preclinical Drug Testing Core (Zero Childhood Cancer Personalised Medicine Program).

A/Prof Arndt has held several university positions and is currently Associate Professor (Conjoint) in the School of Clinical Medicine (UNSW Medicine). Prior to joining CCI, he was Research Director of the Target Discovery Program at Johnson & Johnson Research, where he spent 16 years in increasingly senior roles. His research interests/expertise span target discovery and validation, development of novel technology platforms and HTS, early-stage drug discovery, development of unique cell-based platforms for personalised medicine, and translation of novel biological discoveries into the clinic.